Development of pneumococcal vaccines over the last 10 years

References

• Cohen R, Cohen JF, Chalumeau M, et al. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. Expert Rev Vaccines. 2017;16:625–640.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Pharmacotherapy for pneumococcal infections: an update. Expert Opin Pharmacother. 2013;14:65–77.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008 Available at: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/. Accessed on 2017 Jun 13.
   Google Scholar
• Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Atkinson W, Wolfe S, Hamborsky J eds. 12th. second printing. Washington DC: Public Health Foundation. 2012.
   Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29:3398–3412.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease. Available at: https://www.cdc.gov/pneumococcal/about/facts.html. Accessed on: June 11, 2017.
   Google Scholar
• Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis. 1981;3(Suppl):S1–17.
   PubMedGoogle Scholar
• Bruyn GA, Van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis. 1991;10:897–910.
   PubMed Web of Science ®Google Scholar
• Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine. 1998;16:1391–1395.
   PubMed Web of Science ®Google Scholar
• De Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015–1023.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines. 2013;12:1379–1394.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187–195.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–897.
   PubMedGoogle Scholar
• Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis. 2012;54:1765–1773.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179–1186.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Synflorix. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000973/human_med_001071.jsp&mid=WC0b01ac058001d124. Accessed on: June 13, 2017.
   Google Scholar
• Food and Drug Administration. Prevnar 13. Available at: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201669.pdf. Accessed on: June 13, 2017.
   Google Scholar
• Esposito S, Principi N. Safety and tolerability of pneumococcal vaccines in children. Expert Opin Drug Saf. 2016;15:777–785.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med. 2014;2:717–727.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiol. 2015;10:1599–1607.
   PubMed Web of Science ®Google Scholar
• Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng. 2012;109:1443–1460.
   PubMed Web of Science ®Google Scholar
• Geno KA, Saad JS, Nahm MH. Discovery of novel pneumococcal serotype 35D, a natural WciG-deficient variant of serotype 35B. J Clin Microbiol. 2017;55:1416–1425.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100–121.
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12:e0177113.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83–93.
   PubMed Web of Science ®Google Scholar
• Azzari C, Cortimiglia M, Nieddu F, et al. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: should we expect herd protection of adults through infants’ vaccination? Hum Vaccin Immunother. 2016;12:344–350.
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22:10–16.
   PubMed Web of Science ®Google Scholar
• Kilpi T, Ahman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis. 2003;37:1155–1164.
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367:740–748.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Prevention of community-acquired pneumonia with available pneumococcal vaccines. Int J Mol Sci. 2016;25:18–30.
   Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–1125.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.
   PubMed Web of Science ®Google Scholar
• Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006–2015. Pediatr Infect Dis J. 2016;35:901–906.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Center KJ, Barson WJ, et al. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2015;60:1339–1345.
   PubMed Web of Science ®Google Scholar
• Marchisio P, Esposito S, Picca M, et al. Serotypes not included in 13-valent pneumococcal vaccine as causes of acute otitis media with spontaneous tympanic membrane perforation in a geographic area with high vaccination coverage. Pediatr Infect Dis J. 2017;36:521–523.
   PubMed Web of Science ®Google Scholar
• Desai AP, Sharma D, Crispell EK, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J. 2015;34:1168–1174.
   PubMed Web of Science ®Google Scholar
• Neves FPG, Cardoso NT, Snyder RE, et al. Pneumococcal carriage among children after four years of routine 10-valent pneumococcal conjugate vaccine use in Brazil: the emergence of multidrug resistant serotype 6C. Vaccine. 2017;35:2794–2800.
   PubMed Web of Science ®Google Scholar
• Kawaguchiya M, Urushibara N, Kobayashi N. Multidrug resistance in non-PCV13 serotypes of Streptococcus pneumoniae in northern Japan, 2014. Microb Drug Resist. 2017;23:206–214.
   PubMed Web of Science ®Google Scholar
• McElligott M, Vickers I, Meehan M, et al. Noninvasive pneumococcal clones associated with antimicrobial nonsusceptibility isolated from children in the era of conjugate vaccines. Antimicrob Agents Chemother. 2015;59:5761–5767.
   PubMed Web of Science ®Google Scholar
• Golden AR, Adam HJ, Gilmour MW, et al. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011–13. J Antimicrob Chemother. 2015;70:1960–1964.
   PubMed Web of Science ®Google Scholar
• Chochua S, Metcalf BJ, Li Z, et al. Invasive serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015–2016. Emerg Infect Dis. 2017;23:922–930.
   PubMed Web of Science ®Google Scholar
• Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(Suppl 3):16–20.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Little BA, Finkelstein J, et al. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine. 2017;35:4002–4009.
   PubMed Web of Science ®Google Scholar
• Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58:6484–6489.
   PubMed Web of Science ®Google Scholar
• Kawaguchiya M, Urushibara N, Aung MS, et al. Serotype distribution, antimicrobial resistance and prevalence of pilus islets in pneumococci following the use of conjugate vaccines. J Med Microbiol. 2017;66:643–650.
   PubMed Web of Science ®Google Scholar
• GAVI. The Vaccine Alliance. Annual Progress Report. Available at: www.GAVI.com. Accessed on: June 13, 2017.
   Google Scholar
• Rodgers GL, Klugman KP. Surveillance of the impact of pneumococcal conjugate vaccines in developing countries. Hum Vaccin Immunother. 2016;12:417–420.
   PubMed Web of Science ®Google Scholar
• PATH. Center for Vaccine Innovation and Access. Available at: http://sites.path.org/cvia. Accessed on: June 13, 2017.
   Google Scholar
• Idoko OT, Mboizi RB, Okoye M, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: an open-label randomized controlled trial. Vaccine. 2017;35:3256–3263.
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Alderson MR. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today (Barc). 2011;47:207–214.
   PubMed Web of Science ®Google Scholar
• Alderson MR. Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016;34:2959–2961.
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Gov. Study immunogenicity and safety of 13-valent pneumococcal conjugate vaccine. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02079207. Accessed on: June 13, 2017.
   Google Scholar
• Turner AEB, Je G, Hy S, et al. Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae. Synthetic Syst Biotechnol. 2017;2:49–58.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Yuan L, Huang Z, et al. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China. BMJ Open. 2016;6:e012488.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010;29:283–288.
   PubMed Web of Science ®Google Scholar
• Sobanjo-Ter Meulen A, Vesikari T, Malacaman EA, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:186–194.
   PubMed Web of Science ®Google Scholar
• McFetridge R, Meulen AS, Folkerth SD, et al. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2015;33:2793–2799.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Whitney CG, Zell E, et al. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med. 2005;2:e15.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Khan MN, Xu Q. Next generation protein based Streptococcus pneumoniae vaccines. Hum Vaccin Immunother. 2016;12:194–205.
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Weiser JN, Paton JC, et al. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol. 2008;6:288–301.
   PubMed Web of Science ®Google Scholar
• Malley R, Trzcinski K, Srivastava A, et al. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA. 2005;102:4848–4853.
   PubMed Web of Science ®Google Scholar
• Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–776.
   PubMed Web of Science ®Google Scholar
• Li Y, Gierahn T, Thompson CM, et al. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog. 2012;8:e1002989.
   PubMed Web of Science ®Google Scholar
• Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother. 2016;12:383–392.
   PubMed Web of Science ®Google Scholar
• Andre GO, Converso TR, Politano WR, et al. Role of Streptococcus pneumoniae proteins in evasion of complement-mediated immunity. Front Microbiol. 2017;8:224.
   PubMed Web of Science ®Google Scholar
• Mirza S, Benjamin WHJ, Coan PA, et al. The effects of differences in PspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin. Microb Pathog. 2016;99:209–219.
   PubMed Web of Science ®Google Scholar
• Hollingshead SK, Becker R, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun. 2000;68:5889–5900.
   PubMed Web of Science ®Google Scholar
• Briles DE, King JD, Gray MA, et al. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine. 1996;14:858–6728.
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis. 2000;182:1694–1701.
   PubMed Web of Science ®Google Scholar
• McCool TL, Cate TR, Tuomanen EI, et al. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun. 2003;71:5724–5732.
   PubMed Web of Science ®Google Scholar
• Frey SE, Lottenbach KR, Hill H, et al. A phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine. 2013;31:4874–4880.
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Nahm MH, Khambaty FM, et al. Issues and challenges in the development of pneumococcal protein vaccines. Expert Rev Vaccines. 2012;11:279–285.
   PubMed Web of Science ®Google Scholar
• Khan MN, Sharma SK, Filkins LM, et al. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect. 2012;14:1102–1110.
   PubMed Web of Science ®Google Scholar
• Glover DT, Hollingshead SK, Briles DE. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun. 2008;76:2767–2776.
   PubMed Web of Science ®Google Scholar
• Kaur R, Surendran N, Ochs M, et al. Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun. 2014;82:5069–5075.
   PubMed Web of Science ®Google Scholar
• Xu Q, Casey JR, Almudevar A, et al. Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children. Clin Microbiol Infect. 2017;23:487.e1–487.e6.
   PubMed Web of Science ®Google Scholar
• Xu Q, Pryharski K, Pichichero ME. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model. Vaccine. 2017;35:337–344.
   PubMed Web of Science ®Google Scholar
• Bologa M, Kamtchoua T, Hopfer R, et al. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine. 2012;30:7461–7468.
   PubMed Web of Science ®Google Scholar
• Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine. 2014;32:3025–3034.
   PubMed Web of Science ®Google Scholar
• Brooks WA, Chang LJ, Sheng X, et al. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study. Vaccine. 2015;33:4610–4617.
   PubMed Web of Science ®Google Scholar
• Hirst RA, Kadioglu A, O’callaghan C, et al. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol. 2004;138:195–201.
   PubMed Web of Science ®Google Scholar
• Alexander JE, Lock RA, Peeters CC, et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994;62:5683–5688.
   PubMed Web of Science ®Google Scholar
• Kamtchoua T, Bologa M, Hopfer R, et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013;31:327–333.
   PubMed Web of Science ®Google Scholar
• Odutola A, Ota MO, Ogundare EO, et al. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2–4 years: a phase II randomized study. Hum Vaccin Immunother. 2016;12:393–402.
   PubMed Web of Science ®Google Scholar
• Prymula R, Szenborn L, Silfverdal SA, et al. Immunogenicity of primary vaccination with an investigational protein-based pneumococcal vaccine in infants in Europe: a phase II randomized trial. Hyderabad, India: ISPPD-Abstract 0551 2014; 2014 March 9–13.
   Google Scholar
• Odutola A, Ota MO, Antonio M, et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study. Vaccine. 2017;35:2531–2542.
   PubMed Web of Science ®Google Scholar
• Khan MN, Pichichero ME. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine. 2012;30:2900–2907.
   PubMed Web of Science ®Google Scholar
• Godfroid F, Hermand P, Verlant V, et al. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun. 2011;79:238–245.
   PubMed Web of Science ®Google Scholar
• Whaley MJ, Sampson JS, Johnson SE, et al. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine. 2010;28:3071–3075.
   PubMed Web of Science ®Google Scholar
• Talkington DF, Brown BG, Tharpe JA, et al. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog. 1996;21:17–22.
   PubMed Web of Science ®Google Scholar
• Nagy E editor. IC47, a novel protein-based pneumococcal vaccine: from bench to the clinic. ISPPD Abstract 031 2010: Tel Aviv, Israel. March 14–18. 2010.
   Google Scholar
• Giefing C, Meinke AL, Hanner M, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med. 2008;205:117–131.
   PubMed Web of Science ®Google Scholar
• Schmid P, Selak S, Keller M, et al. Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine. 2011;29:3982–3989.
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Gierahn TM, Lu YJ, et al. T(h)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe. 2011;9:158–165.
   PubMed Web of Science ®Google Scholar
• Moffitt K, Skoberne M, Howard A, et al. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun. 2014;82:2079–2086.
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. ClinicalTrials.gov NCT02116998. Available at: https://clinicaltrials.gov/ct2/show/NCT02116998?term=NCT02116998&rank=1 Accessed on: June 13, 2017.
   Google Scholar
• Genocea Biosciences. Genocea announces top-line results from phase 2a trial for universal pneumococcal vaccine candidate GEN-004. Available at: http://ir.genocea.com/releasedetail.cfm?releaseid=937136. Accessed on: June 13, 2017.
   Google Scholar
• Biotech F. Genocea halts its antibiotic vaccine program after a Phase II failure. Available at: http://www.fiercebiotech.com/r-d/genocea-halts-its-antibiotic-vaccine-program-after-a-phase-ii-failure. Accessed on: June 13, 2017.
   Google Scholar
• Lu YJ, Leite L, Gonçalves VM, et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine. 2010;28:7468–7475.
   PubMed Web of Science ®Google Scholar
• Malley R, Lipsitch M, Stack A, et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun. 2001;69:4870–4873.
   PubMed Web of Science ®Google Scholar
• Malley R, Morse SC, Leite LCC, et al. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun. 2004;72:4290–4292.
   PubMed Web of Science ®Google Scholar
• Lu YJ, Yadav P, Clements JD, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol. 2010;17:1005–1012.
   PubMed Web of Science ®Google Scholar
• Alderson M, Malley R, Anderson P, et al. A phase 1 study to assess the safety, tolerability and immunogenicity of inactivated non-encapsualted Streptococcus pneumoniae whole cell vaccine.Hyderabad, India: ISPPD- Abstract 0121 2014. 2014 March 9–13.
   Google Scholar
• U.S. National Institutes of Health. Clinical Trial.gov. NCT02097472. Available at: https://clinicaltrials.gov/ct2/show/NCT02097472?cond=pneumococcal±whole±cell±vaccine&rank=1. Accessed on: June 14, 2017.
   Google Scholar
• Babb R, Chen A, Hirst TR, et al. Intranasal vaccination with γ-irradiated Streptococcus pneumoniae whole-cell vaccine provides serotype-independent protection mediated by B-cells and innate IL-17 responses. Clin Sci (Lond). 2016;130:697–710.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommendations for the production and control pf pneumococcal conjugate vaccineess. WHO Tech Rep Ser. 2005;927:1–154.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O. Pneumococcal conjugate vaccination: correlates of protection. Lancet Infect Dis. 2014;14:784–786.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines. Hum Vaccin Immunother. 2015;11:1494–1500.
   PubMed Web of Science ®Google Scholar
• Cvitkovic Spik V, Beovic B, Pokorn M, et al. Improvement of pneumococcal pneumonia diagnostics by the use of rt-PCR on plasma and respiratory samples. Scand J Infect Dis. 2013;45:731–737.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Nohynek H, World health organization pneumococcal vaccine trials carriage working group. Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003;22:133–140.
   PubMed Web of Science ®Google Scholar
• Principi N, Terranova L, Zampiero A, et al. Oropharyngeal and nasopharyngeal sampling for the detection of adolescent Streptococcus pneumoniae carriers. J Med Microbiol. 2014;63:393–398.
   PubMed Web of Science ®Google Scholar
• Scott P, Herzog SA, Auranen K, et al. Timing of bacterial carriage sampling in vaccine trials: a modelling study. Epidemics. 2014;9:8–17.
   PubMed Web of Science ®Google Scholar
• Auranen K, Rinta-Kokko H, Halloran ME. Estimating strain-specific and overall efficacy of polyvalent vaccines against recurrent pathogens from a cross-sectional study. Biometrics. 2013;69:235–244.
   PubMed Web of Science ®Google Scholar